Evidence, Coverage and Incentives: Challenges in Personalized Medicine
Personalized medicine is greatly changing the way medicine is practiced, as well as how drugs and biologics are developed. Today patients are benefiting from targeted therapies with fewer side effects, and doctors have more tools available to practice medicine more effectively.
Personalized medicine is greatly changing the way medicine is practiced, as well as how drugs and biologics are developed. Today patients are benefiting from targeted therapies with fewer side effects, and doctors have more tools available to practice medicine more effectively.
But there are policy, economic and regulatory disincentives that are having a profound effect on the development of novel molecular diagnostic products. To explore these challenges and potential solutions, the Personalized Medicine Coalition (PMC) and the Biotechnology Industry Organization (BIO) are bringing together stakeholders for a daylong summit, "Evidence, Coverage & Incentives," on April 17 in Washington, DC.
Featured speakers include James C. Greenwood, president and CEO, Biotechnology Industry Organization; Dr. Edward Abrahams, president, Personalized Medicine Coalition; Dr. Louis Jacques, director, coverage and analysis group, Centers for Medicare and Medicaid Services; and Dr. Jeff Allen, executive director, Friends of Cancer Research, among other notable health care experts. Discussions will focus on topics such as
- Challenges of reimbursement;
- Evidentiary standards and data requirement for payer coverage;
- Clinical guidelines;
- Investing in molecular diagnostics;
- Issues impacting market access; and
- Incentivizing personalized medicine development.
The summit, sponsored by the National Pharmaceutical Council and other health organizations, is the first in a series of “PMC/BIO Solutions Summits” to convene stakeholders in discussions about potential solutions to these important barriers.